MicroRNA-302b mitigates renal fibrosis via inhibiting TGF-β/Smad pathway activation

Mengkui Sun¹,²*, Wei Zhou¹,²*, Fei Yao¹,²*, Jianming Song³*, Yanan Xu¹,²*, Zhimei Deng¹,²*, Hongwang Diao¹,²* and Shoulin Li¹,²**

¹Department of Urology, Shenzhen Children’s Hospital, Shenzhen, Guangdong Province, China
²Laboratory of Pelvic Floor Muscle Function, Shenzhen Children’s Hospital, Shenzhen, Guangdong Province, China
³Department of Pathology, Shenzhen Children’s Hospital, Shenzhen, Guangdong Province, China

Abstract
Renal fibrosis is one of the most significant pathological changes after ureteral obstruction. Transforming growth factor-β (TGF-β) signaling pathway plays essential roles in kidney fibrosis regulation. The aims of the present study were to investigate effects of microRNA-302b (miR-302b) on renal fibrosis, and interaction between miR-302b and TGF-β signaling pathway in murine unilateral ureteral obstruction (UUO) model. Microarray dataset GSE42716 was downloaded by retrieving Gene Expression Omnibus database. In accordance with bioinformatics analysis results, miR-302b was significantly down-regulated in UUO mouse kidney tissue and TGF-β1-treated HK-2 cells. Masson’s trichrome staining showed that miR-302b mimics decreased renal fibrosis induced by UUO. The increased mRNA expression of collagen I and α-smooth muscle actin (α-SMA) and decreased expression of E-cadherin were reversed by miR-302b mimics. In addition, miR-302b up-regulation also inhibited TGF-β1-induced epithelial mesenchymal transition (EMT) of HK-2 cells by restoring E-cadherin expression and decreasing α-SMA expression. miR-302b mimics suppressed both luciferase activity and protein expression of TGF-β/Smad signaling pathway in vivo and in vitro. Furthermore, over-expression of TGF-βR2 restored the miR-302b-induced decrease of collagen I and α-SMA expression. In conclusion, this study demonstrated that miR-302b attenuated renal fibrosis by targeting TGF-β/Smad signaling activation. Our findings showed that elevating renal miR-302b levels may be a novel therapeutic strategy for preventing renal fibrosis.

Key words: MicroRNA-302b; Renal fibrosis; Epithelial mesenchymal transition; TGF-β receptor 2; Unilateral ureteral obstruction

Introduction
Obstructive nephropathy leads to almost 30–50% of all end-stage renal disease cases in infants and children (1). Ureteropelvic junction obstruction is the most common etiology of congenital urinary tract obstruction. During ureteral obstruction, increased synthesis of angiotensin II, cytokines, and growth factors are identified as causative factors that result in renal interstitial fibrosis characterized by infiltration of inflammatory cells, accumulation of activated myofibroblasts, extracellular matrix proteins deposition, and tubular cell damage (2). Renal interstitial fibrosis impedes the normal function of tubules and glomerulus. Unfortunately, there is still no effective treatment to specifically inhibit or reverse renal interstitial fibrosis before or after surgical intervention. However, it has been demonstrated that transforming growth factor-β (TGF-β)/α-smooth muscle actin (Smad) signaling plays a vital role in renal fibrosis pathogenesis (3). Therefore, intervention of the TGF-β/Smad signaling pathway may benefit renal fibrosis prevention. MicroRNAs, approximately 20–25 nucleotides long, are small endogenous single-stranded non-coding RNAs that exhibit negative characters after gene transcription through binding to the 3' untranslated region of target gene mRNA (4). Hence, aberrant expression of miRNAs participates in numerous pathologic processes including cancer, diabetes, and myocardial disease (5–7). In addition, accumulating reports have demonstrated that miRNAs play important roles in the progression of renal fibrosis. In a mouse diabetic nephropathy renal fibrosis model, mir-377 is up-regulated and results in increased expression of fibronectin protein, which is a fundamental matrix protein in renal fibrosis (8). Another study

Correspondence: Shoulin Li: <etylshoulin@163.com>

*These authors contributed equally to this study.

Received October 11, 2019 | Accepted August 31, 2020
demonstrates that miR-200a and miR-141, two members of the miR-200 family, can enhance E-cadherin protein expression by targeting zinc finger E-box-binding homeobox (ZEB) 1 and ZEB2. Hence, miR-200a and miR-141 can decrease TGF-β1-induced tubular epithelial-to-mesenchymal transition (EMT), which plays crucial roles in the progression of renal fibrosis (9). Furthermore, miR-433 is proven to decrease Azin1 expression which, in turn, activates TGF-β/Smad3 pathway and the fibrotic response (10). These studies indicate the possibility of renal fibrosis prevention by miRNAs regulation.

Unilateral ureteral obstruction (UUO) is a widely applied experimental animal model for renal interstitial fibrosis (11). The aims of the present study were to investigate the effects of microRNA-302b (miR-302b) on renal fibrosis and to determine the interaction between miR-302b and TGF-β signaling pathway in the murine UUO model.

Material and Methods

Reagents

miR-302b mimics, miR-302b inhibitor, and corresponding negative control oligonucleotides were purchased from GenePharma (China). Adeno-associated virus encoding miR-302 mimic or negative control were obtained from Oobio (China). Human renal proximal tubular epithelial (HK-2) cells were obtained from the American Type Culture Collection (ATCC, USA). DMEM/F12, fetal bovine serum (FBS), penicillin, streptomycin, and TGF-β (Sigma Aldrich, USA) were used for subsequent experiments. The mouse UUO procedure was performed under intraperitoneal 4% chloral hydrate anesthesia, and the dose of chloral hydrate used for anesthesia of mice was 10 mL drug per kg animal body weight. The mouse UUO procedure was performed under intraperitoneal 4% chloral hydrate anesthesia, and the dose of chloral hydrate used for anesthesia of mice was 10 mL drug per kg animal body weight. The mouse UUO procedure was performed under intraperitoneal 4% chloral hydrate anesthesia, and the dose of chloral hydrate used for anesthesia of mice was 10 mL drug per kg animal body weight.

Data resources

MicroRNA expression profile GSE42716, which includes 4 UUO samples and 4 normal samples, was obtained from the Gene Expression Omnibus (GEO) database (NCBI, USA).

Analysis of differential expression miRNAs

GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r/), which is based on the Limma R and GEOquery packages, is a convenient online tool that performs comparisons on GEO datasets. Differential expression analysis of miRNAs between control group and UUO group was carried out using the GEO2R program. The cut-off criteria were set as P-value < 0.05 and |log fold change| > 2 for identifying differential expression miRNAs.

Prediction of target genes

The potential target genes of miR-302b were predicted by TargetScan (http://www.target-scan.org/mmu_71/).

Animal model of UUO

All experiments were conducted in 6 ~ 8-week-old ICR male mice, weighing 23 ~ 26 g, obtained from Guangdong Medical Laboratory Animal Center (China). Animals were kept with free access to rodent food and clean water on a normal circadian rhythm. All procedures were approved by the Institutional Animal Care and Use Committee of Shantou University Medical College (China). All surgical procedures were performed under intraperitoneal 4% chloral hydrate anesthesia, and the dose of chloral hydrate used for anesthesia of mice was 10 mL drug per kg animal body weight. The mouse UUO procedure was performed under intraperitoneal 4% chloral hydrate anesthesia, and the dose of chloral hydrate used for anesthesia of mice was 10 mL drug per kg animal body weight.

Cell culture and transfection

HK-2 cells were cultured in DMEM/F12 (HyClone; GE Healthcare, USA) medium supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., USA), 100 IU/mL streptomycin, and 100 IU/mL penicillin (Sigma Aldrich, USA) at 37°C and 5% CO2. For cell transfection, miR-302b mimics, miR-302b inhibitor, or corresponding negative control were diluted with Opti-MEM I medium (Thermo Fisher Scientific, USA) and subsequently transfected into HK-2 cells using Lipofectamine 2000 (Invitrogen, USA). TGF-β1R2 human cDNA ORF clone was purchased from KeyGen Biotec (China) and purified as previously described (12). HK-2 cells were transfected with TGF-β1R2 plasmid or an empty vector by Lipofectamine 2000.

Quantitative real-time PCR for miRNA and mRNA

Total RNA was extracted from kidney tissues or cells with TRIzol Reagent (Invitrogen), following to the manufacturer’s instructions as previously described (12). Total RNA with the OD260/OD280 ratio between 1.7 and 2.1 was used for subsequent experiments. The first strand of cDNA was synthesized using a First-strand cDNA synthesis kit (Invitrogen). Quantitative real-time PCR was carried out subsequently to detect relative expression levels of miRNA and mRNA using the Quanti-Tect SYBR Green PCR mixture on an ABI 7500 fast real-time PCR system (Applied Biosystems, USA). The expression levels of U6 and β-actin were utilized for normalization of miRNAs and mRNA, respectively. The reaction conditions were: 2 min at 95°C, 25 s at 96°C, and 30 s at 63°C for 35 cycles. Relative expression levels of miR-302b and miRNAs were calculated by the 2^–ΔΔCT method. Primers for miR-302b and U6 were purchased from Ruibo (China). The primers for detection of miRNAs were as follows: collagen I (human), 5'-TGACGAGACCAAGAAGCTCC-3' (forward) and 5'-GCACCATATTCCACAGGC-3' (reverse); α-SMA (human), 5'-CCCGGGACTAAGACGGAAT-3' (forward) and 5'-CCATCACCCTGATGTCTG-3' (reverse); E-Cadherin (human), 5'-GCTGGACCAGAGAGGTTTC-3' (forward) and 5'-CAAAAAATCAAAGGCCCAGGTG-3' (forward).
(reverse); GAPDH (human), 5′-AATGGGCAGCCGTTAG
GAAA-3′ (forward) and 5′-GCCGCCAAATACGAACAAA
TC-3′ (reverse); Collagen I (mouse), 5′-GAGAGGGTAA
CAAGTCCCG-3′ (forward) and 5′-AAACCTCTCTCGC
CTCTTGC-3′ (reverse); α-SMA (mouse), 5′-CCTCCGTG
ACTACTGGCAG-3′ (forward) and 5′-GTCAGCAATGC
CTGGTATCAT-3′ (reverse); E-Cadherin (mouse), 5′-CC
CGAATAAGAAGGGGC-3′ (forward) and 5′-TGAC
GATGCTTAGGGCATG-3′ (reverse); GAPDH (mouse),
5′-GACCTTCATGCTCATGAG-3′ (forward) and 5′-
CCGCATTTAAACCAGGAGGAGG-3′ (reverse).

Histopathological analysis
Renal tissues from the four groups were fixed in 10% neutral buffered formalin, paraffin-embedded, and cut into 4-μm thick sections. The sections were then stained with Masson’s trichrome staining (Solarbio, China). Tubulointerstitial fibrosis was assessed based on Masson’s trichrome staining according to a previous study (13).

Western blot analysis
The mouse renal tissues or HK-2 cells were lysed by RIPA lysis buffer (Beyotime, China) with 1% protease inhibitor cocktail (Roche, USA). Protein concentration was measured using a bicinchoninic acid kit (Thermo Scientific). After electrophoresis of samples on 6~12% sodium dodecyl sulfate polyacrylamide gel, proteins were transferred onto a nitrocellulose membrane (Bio-Rad). The bands were visualized using the ECL Western blotting detection kit (Bio-Rad) and analyzed with ImageJ software (Version 1.8.0, National Institutes of Health, USA).

 Luciferase reporter gene assay
The luciferase reporter gene was detected using a Dual-Luciferase Reporter Assay System (Promega, USA). The 3′-UTR seed sequence containing TGF-βR1 binding with miR-302b and mutated sequences were synthesized and cloned into the pmirGLO-REPORT Luciferase Vector (Promega). HK-2 cells were transfected with 200 ng miR-302b mimics or miR-302b inhibitors, subsequently co-transfected with 40 ng of the wild-type or mutant reporter vector using Lipofectamine 2000 (Invitrogen). Luciferase assay was conducted on cell lysates of the cells 48 h after transfection using Dual-Luciferase Assay System (Promega) according to the manufacturer’s protocol. pmirGLO report vector was utilized as a positive control.

Statistical analysis
The results are reported as means ± SE. Comparisons between groups were performed using unpaired two tailed Student’s t test or ANOVA, as appropriate. All statistical analyses were conducted using SPSS 19.0 (IBM, USA). P values less than 0.05 were regarded as statistically significant.

Results
Expression of miR-302b in renal tissue of UUO mice and TGF-β1-treated HK-2 cells
A total of 118 differentially expressed miRNAs including 71 upregulated and 47 downregulated were classified in the UUO group compared with the sham group. Differential expression miRNAs are reported as a volcano plot in Figure 1A. As shown in Figure 1B, miR-302b was significantly down-regulated in the UUO group. RT-PCR assay results showed that in the UUO group renal tissue, the expression of miR-302b was significantly down-regulated compared to the control group (Figure 1C). Furthermore, TGF-β1 treated HK-2 cells showed lower miR-302b expression (Figure 1D).

Renal fibrosis and EMT progression were inhibited by miR-302b in UUO mice
As shown in Figure 2A and B, the percentage of Masson’s trichrome staining positive area increased after UUO operation compared with the control group. However, miR-302b mimics decreased renal fibrosis detected by Masson’s trichrome staining assay. Furthermore, expression of collagen I was down-regulated by miR-302b mimic shown by RT-PCR assay (Figure 2C). Previous studies have demonstrated a vital role of EMT progression in renal fibrosis. We confirmed that mRNA expression of α-SMA increased while E-cadherin decreased after UUO, and miR-302b mimics reversed those trends (Figure 2D and E).

TGF-β1-induced EMT was arrested by miR-302b mimics in HK-2 cells
miR-302b mimic or negative control (NC) was transfected to HK-2 cells. Then cells were incubated with TGF-β1 (5 ng/mL) or corresponding vehicle (saline) for another 48 h. Compared with the vehicle group, TGF-β1-treated HK-2 cells showed lower E-cadherin (Figure 3A and B) and higher α-SMA expression (Figure 3C and D). However, in TGF-β1-treated cells, expression of E-cadherin was up-regulated (Figure 3A and B) and α-SMA expression was down-regulated in the miR-302b mimics-treated group compared to the NC group (Figure 3C and D).
MiR-302b targeted TGF-βR2 directly

To explore underlying mechanisms of miR-302b regulating renal fibrosis, a computational mRNA target online analysis (www.targetscan.org) was conducted to predict potential target genes of miR-302b. Interestingly, miR-302b might directly target TGF-βR2 by binding to its 3′-UTR in mouse and human (Figure 4A). To further verify this prediction, firefly luciferase reporter constructs containing a wild-type or mutant 3′-UTR of TGF-βR2 was generated and luciferases reporter analysis was performed. miR-302b mimic significantly inhibited, while miR-302b inhibitor increased, the luciferase activity of TGF-βR2 3′-UTR. However, both miR-302b mimic and miR-302b inhibitor had no effect on the luciferase activity of luciferase reporter incorporating TGF-βR2 3′-UTR with the mutant miR-302b binding sites (Figure 4B and C). Consistent with the observation in TGF-βR2 3′-UTR reporter luciferase, miR-302b mimics significantly reduced TGF-βR2 protein expression while miR-302b inhibitor increased TGF-βR2 protein expression (Figure 4D and E). To sum up, TGF-βR2 was a target gene of miR-302b.

MiR-302b mimics alleviated renal fibrosis and EMT by blocking TGF-β1/Smad signaling pathway in vivo and in vitro

As shown in Figure 5A, in control mice, no difference in TGF-β1 mRNA expression was observed in miR-302b-treated mice or NC. However, in UUO mice, miR-302b mimics significantly reduced TGF-β1 expression in mRNA level. Moreover, whether treated with miR-302b mimics or NC, there were no obvious differences of Smad-2 and Smad-3 phosphorylation in the control group mice, while miR-302b mimics decreased Smad-2 and Smad-3 phosphorylation in UUO mice (Figure 5B and C). In accordance with in vivo findings, miR-302 mimics inhibited TGF-β1-induced TGF-βR2 expression (Figure 5D), and Smad-2 and Smad-3 phosphorylation (Figure 5E and F) in HK-2 cells. Furthermore, TGF-β1-induced collagen I and α-SMA accumulation were abolished by miR-302 mimics (Figure 5D).

Discussion

Progressive renal fibrosis is an end-stage of obstructive nephropathy and results in renal insufficiency (1). Until
now, no effective therapeutic strategy exists for renal fibrosis (14). Therefore, it is imperative to explore the exact cellular and molecular mechanisms of this pathologic process.

MicroRNAs are a group of noncoding small RNAs approximately 22 nucleotides in length. By binding to 3'-untranslated regions of mRNA, miRNAs can suppress translation of target genes (15). miR-302b has been...
miR-302b alleviates renal fibrosis

proven to be involved in many important pathologic processes including suppressing lung cancer cell proliferation (16), inhibiting osteosarcoma cell invasion (17), and accelerating the skin aging process (18). Recently, more and more studies have focused on the interaction between miR-302 family members and renal cell fibrosis. The expression of miR-302d is increased in UUO mouse, and miR-302d inhibits epithelial mesenchymal transition progression of renal HKC8 epithelial cells induced by TGF-β1 (19). Microvesicles released from mesenchymal stem cells incubated in erythropoietin restore kidney damage caused by UUO in vivo and increased miR-302b expression. In addition, these microvesicles inhibit HK-2 cell fibrosis induced by TGF-β1. This study indicates that miR-302b may contribute to renal fibrosis prevention (20). A recent study demonstrates that overexpression of miR-302 facilitates human mesangial cell plasticity characterized by increased expression of Snail (21). Mesangial cells can participate in the progression of renal glomerular fibrosis by secreting inflammatory cytokines, adhesion molecules, and chemokines (22). Moreover, Snail-induced EMT process contributes to tubulointerstitial fibrosis in diabetic nephropathy (23). In addition, miR-302c is proven to prevent mesothelial cells fibrosis and mesothelial-mesenchymal transition induced by TGF-β1 through targeting connective tissue growth factor during peritoneal dialysis (24). In summary, these studies suggest that miR-302 family members may function as protective factors in the pathological process of cell fibrosis, especially renal cells.

In our present study, microarray analysis revealed that kidney miR-302b was significantly decreased after UUO in mice. According to this finding, we established a mouse UUO model. In accordance with the results of microarray analysis, the expression of miR-302b was down-regulated in the UUO group compared with the control group detected by qRT-PCR. TGF-β1-treated human kidney tubular cells (HK-2 cells) is a classical in vitro model of renal cell fibrosis (25,26). We found a significant decrease in expression of miR-302b in TGF-β1 treated HK-2 cells, which was similar to the in vivo results. These initial results suggested miR-302b may participate in renal fibrosis progression both in vivo and in vitro. To verify this hypothesis, miR-302b mimics or negative control sequences were injected in both UUO and sham-operation mice. Results demonstrated that miR-302b attenuated renal fibrosis detected by Masson’s trichrome staining. Meanwhile, miR-302b up-regulation suppressed type I collagen and α-SMA expression and increased E-cadherin expression. Previous studies have demonstrated that collagen I, an important component of interstitial extracellular matrix, is up-regulated during renal fibrosis (27,28). Increased α-SMA expression and loss of E-cadherin indicates renal cells undergo EMT, which is an important part of renal fibrosis (29,30). EMT involving injured epithelial cells performs vital roles in the pathological process of renal fibrosis. Tubular epithelial cells undergoing EMT can obtain a mesenchymal phenotype, which is believed to be a source of myofibroblasts/fibroblasts (31,32). Myofibroblasts have been demonstrated to be an important contributor of collagen I synthesis during renal fibrosis (33). Results from animal experiments show that miR-302b alleviates renal fibrosis through inhibiting unusual accumulation of extracellular matrix.
matrix and EMT of renal cells. Whether miR-302b has effects on EMT of renal tubular epithelial cells is still unknown. TGF-β1 is considered to be a key factor to induce EMT of renal tubular epithelial cells during renal fibrosis progression (9). In line with results obtained from in vivo experiments, HK-2 cells treated with TGF-β1 mimicked or negative control sequences for 48 h, then treated with TGF-β1 (5 ng/mL) or saline for another 24 h. Expression of Smad2 and p-Smad2 (C) and of Smad3 and p-Smad3 (D) were detected by Western blot assay. qRT-PCR analysis of collagen I (E) and α-SMA (F) expression in HK-2 cells cotransfected with miR-302b mimic and TGF-βR2 vector for 48 h and then incubated with TGF-β1 or saline for another 24 h. Data are reported as means ± SE (n=8). *P < 0.05 (Student’s t-test or ANOVA). NC-m: miR-302b mimic negative control, 302b-m: miR-302b mimic.

Figure 5. MiR-302b alleviated renal fibrosis and epithelial mesenchymal transition by inhibiting transforming growth factor (TGF)-β signaling pathway activation. Western blot analysis of Smad2 and p-Smad2 (A) and of Smad3 and p-Smad3 (B) expression in unilateral ureteral obstruction and control group mice treated by miR-302b mimic (20 nM) or negative control sequences (20 nM). HK-2 cells were transfected by miR-302b mimic or negative control sequences for 48 h, then treated with TGF-β1 (5 ng/mL) or saline for another 24 h. Expression of Smad2 and p-Smad2 (C) and of Smad3 and p-Smad3 (D) were detected by Western blot assay. qRT-PCR analysis of collagen I (E) and α-SMA (F) expression in HK-2 cells cotransfected with miR-302b mimic and TGF-βR2 vector for 48 h and then incubated with TGF-β1 or saline for another 24 h. Data are reported as means ± SE (n=8). *P < 0.05 (Student’s t-test or ANOVA). NC-m: miR-302b mimic negative control, 302b-m: miR-302b mimic.

To further explore the underlying mechanisms, bioinformatics analysis was conducted. TargetScan database indicated that TGF-βR2 has a target site for miR-302b. TGF-β1 contacting with TGF-βR2 results in recruitment and phosphorylation of TGF-βR1. Then, kinase domains within the receptors are activated (34). In order to validate this prediction, dual-luciferase activity assay and western blot assay were performed. Based on our observations, TGF-βR2 was proven to be a functional target of miR-302b in HK-2 cells. Furthermore, previous studies have demonstrated that targeting TGF-βR2 can inhibit interstitial renal fibrosis in UUO mice via Smad-dependent mechanism (13,35). Activation of Smad2 and Smad3 potentiates several profibrotic gene expressions containing collagens (36), integrins (37), connective tissue growth factor (38), and matrix metalloproteinases (39,40). Therefore, we hypothesized that miR-302b inhibited renal fibrosis by targeting TGF-βR2 via suppressing TGF-β/Smad pathway. Our following in vivo and in vitro experiments supported this hypothesis. Increasing phosphorylation of
Smad2 and Smad3 was observed in kidney tissue after UUO in mice, whereas miR-302b overexpression mitigated this change. In agreement with the in vivo findings, TGF-β1-treated HK-2 cells exhibited high phosphorylation of Smad2 and Smad3. However, miR-302b up-regulation decreased Smad2 and Smad3 phosphorylation. These findings demonstrated that miR-302b suppressed TGF/Smad pathway activation. Moreover, for the sake of exploring a definite relationship between miR-302b and TGF-βR2 in renal fibrosis regulation, we promoted TGF-βR2 expression by transfecting designed TGF-βR2 plasmid into HK-2 cells and observed restoration of collagen I and α-SMA expression compared to miR-302b transfection alone. These results indicated that miR-302b inhibited renal cell fibrosis mainly through targeting TGF-βR2.

In summary, our present study demonstrated for the first time that overexpression of miR-302b attenuated renal fibrosis through suppressing TGF-β1/Smad-dependent pathway by targeting TGF-βR2. These results indicate a possible therapeutic strategy for the prevention of fibrotic kidney diseases.

**Acknowledgments**

This study was funded by Sanming Project of Medicine in Shenzhen (No. SZSM201612013), Shenzhen Medical Key Discipline of Pediatric Surgery (2020-2024) (No. SZXK035), Shenzhen Health System Research Project (No. SZXJ2018045), and Shenzhen Health System Research Project (No. SZFZZ2018055).

**References**

1. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. *Am J Physiol Renal Physiol* 2002; 283: F861–F875, doi: 10.1152/ajprenal.00362.2001.
2. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. *J Am Soc Nephrol* 2010; 21: 1819–1834, doi: 10.1681/ASN.2010080793.
3. Meng XM, Tang PM, Li J, Lan HY. TGF-beta/Smad signaling in renal fibrosis. *Front Physiol* 2015; 6:82, doi: 10.3389/fphys.2015.00082.
4. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell* 2009; 136: 215–233, doi: 10.1016/j.cell.2009.01.002.
5. Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. *Mol Cell Pharmacol* 2011; 3: 83–92.
6. Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. *Nat Rev Cardiol* 2009; 6: 419–429, doi: 10.1038/nrcardio.2009.56.
7. Thur T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature* 2008; 456: 980–984, doi: 10.1038/nature07511.
8. Wang Q, Wang Y, Minto AW, Wang J, Shi Q, Li X, et al. MicroRNA-377 is up-regulated and can lead to increased fibropectin production in diabetic nephropathy. *FASEB J* 2008; 22: 4126–4135, doi: 10.1096/fj.08-112326.
9. Xiong M, Jiang L, Zhou Y, Qiu W, Fang L, Tan R, et al. The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. *Am J Physiol Renal Physiol* 2012; 302: F369–F379, doi: 10.1152/ajprenal.00268.2011.
10. Li R, Chung AC, Dong Y, Yang W, Zhong X, Lan HY. The microRNA miR-433 promotes renal fibrosis by amplifying the TGF-beta/Smad3-Azn1 pathway. *Kidney Int* 2013; 84: 1129–1144, doi: 10.1038/ki.2013.272.
11. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. *Kidney Int* 2009; 75: 1145–1152, doi: 10.1038/ki.2009.86.
12. Fang Y, Xie T, Xue N, Kuang Q, Wei Z, Liang M, et al. miR-382 contributes to renal tubulointerstitial fibrosis by downregulating HSPD1. *Oxid Med Cell Longev* 2017; 2017: 4708516, doi: 10.1155/2017/4708516.
13. Meng J, Li L, Zhao Y, Zhou Z, Zhang M, Li D, et al. MicroRNA-196a/b mitigate renal fibrosis by targeting TGF-beta receptor 2. *J Am Soc Nephrol* 2016; 27: 3006–3021, doi: 10.1681/ASN.2015040422.
14. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. *Nat Rev Nephrol* 2010; 6: 643–656, doi: 10.1038/nrneph.2010.120.
15. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. *Nat Rev Genet* 2012; 13: 271–282, doi: 10.1038/nrg3162.
16. Li J, Yu J, Zhang H, Wang B, Guo H, Bai J, et al. Exosomes-Derived miR-302b suppresses lung cancer cell proliferation and migration via TGFbetaRII inhibition. *Cell Physiol Biochem* 2016; 38: 1715–1726, doi: 10.1159/000443111.
17. Xie Y, Sun W, Deng Z, Zhu X, Hu C, Cai L. MiR-302b suppresses osteosarcoma cell migration and invasion by targeting runx2. *Sci Rep* 2017; 7: 13388, doi: 10.1038/s41598-017-13353-9.
18. Tan J, Hu L, Yang X, Zhang X, Wei C, Lu Q, et al. miRNA expression profiling uncovers a role of miR-302b-3p in regulating skin fibroblasts senescence. *J Cell Biochem* 2020; 21: 70–80, doi: 10.1002/jcb.28862.
19. Faherty N, Curran SP, O’Donovan H, Martin F, Godson C, Brazil DP, et al. CCN2/CTGF increases expression of miR-302 microRNAs, which target the TGFbeta type II receptor with implications for nephropathic cell phenotypes. *J Cell Sci* 2012; 125: 5621–5629, doi: 10.1242/jcs.105528.
20. Wang Y, Lu X, He J, Zhao W. Influence of erythropoietin on microvesicles derived from mesenchymal stem cells protecting renal function of chronic kidney disease. *Stem Cell Res Ther* 2015; 6: 100, doi: 10.1186/s13287-015-0095-0.
21. De Chiara L, Andrews D, Watson A, Oliviero G, Cagney G, et al. miR302 regulates SNAI1 expression to control mesangial cell plasticity. *Sci Rep* 2017; 7: 42407, doi: 10.1038/srep42407.
22. Zhao JH. Mesangial cells and renal fibrosis. *Adv Exp Med Biol* 2019; 1165: 165–194, doi: 10.1007/978-981-13-8871-2.

23. Bai X, Geng J, Zhou Z, Tian J, Li X. MicroRNA-130b improves renal tubulointerstitial fibrosis via repression of Snail-induced epithelial-mesenchymal transition in diabetic nephropathy. *Sci Rep* 2016; 6: 20475, doi: 10.1038/srep20475.

24. Li X, Liu H, Sun L, Zhou X, Yuan X, Chen Y, et al. MicroRNA-302c modulates peritoneal dialysis-associated fibrosis by targeting connective tissue growth factor. *J Cell Mol Med* 2019; 23: 2372–2383, doi: 10.1111/jcmm.14029.

25. Zhang J, Wong MG, Wong M, Gross S, Chen J, Pollock C, et al. A cationic-independent mannose 6-phosphate receptor inhibitor (PXS64) ameliorates kidney fibrosis by inhibiting activation of transforming growth factor-beta1. *Plos One* 2015; 10: e116888, doi: 10.1371/journal.pone.0116888.

26. Luo Q, Cai Z, Tu J, Ling Y, Wang D, Cai Y. Total flavonoids from *Smilax glabra* Roxb blocks epithelial-mesenchymal transition and inhibits renal interstitial fibrosis by targeting miR-21/PTEN signaling. *J Cell Biochem* 2019; 120: 3861–3873, doi: 10.1002/jcb.27668.

27. Bulow RD, Boor P. Extracellular matrix in kidney fibrosis: more than just a scaffold. *J Histochem Cytochem* 2019; 67: 643–661, doi: 10.1369/0022155419849388.

28. Papasotiriou M, Genovese F, Klinkhammer BM, Kunter U, Nielsen SH, Karsdal MA, et al. Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases. *Nephrol Dial Transplant* 2015; 30: 1112–1121, doi: 10.1093/ndt/gfv063.

29. Guarino M, Tosoni A, Nebuloni M. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition. *Hum Pathol* 2009; 40: 1365–1376, doi: 10.1016/j.humpath.2009.02.020.

30. Wang M, Weng X, Guo J, Chen Z, Jiang G, Liu X. Metformin alleviated EMT and fibrosis after renal ischemia-reperfusion injury in rats. *Ren Fail* 2016; 38: 614–621, doi: 10.3109/0886022X.2016.1149770.

31. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. *J Clin Invest* 2002; 110: 341–350, doi: 10.1172/JCI0215518.

32. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. *J Mol Med (Berl)* 2004; 82: 175–181, doi: 10.1007/s00109-005-0517-9.

33. LeBlue VS, Taduri G, O’Connell J, Teng Y, Cooke VG, Woda C, et al. Origin and function of myofibroblasts in kidney fibrosis. *Nat Med* 2013; 19: 1047–1053, doi: 10.1038/nm.3218.

34. Walton KL, Johnson KE, Harrison CA. Targeting TGF-beta mediated SMAD signaling for the prevention of fibrosis. *Front Pharmacol* 2017; 8: 461, doi: 10.3389/fphar.2017.00461.

35. Kushibiki T, Nagata-Nakajima N, Sugai M, Shimizu A, Tabata Y. Delivery of plasmid DNA expressing small interference RNA for TGF-beta type II receptor by cationized gelatin to prevent interstitial renal fibrosis. *J Control Release* 2005; 105: 318–331, doi: 10.1016/j.jconrel.2005.02.030.

36. Verrecchia F, Vindevoghel L, Lechleider RJ, Uitto J, Roberts AB, Mauviel A. Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner. *Oncogene* 2001; 20: 3332–3340, doi: 10.1038/sj.onc.1204448.

37. Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. *Embo Rep* 2010; 11: 97–105, doi: 10.1038/embr.2009.276.

38. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. *Kidney Int* 2002; 62: 1149–1159, doi: 10.1111/j.1523-1755.2002.kid567.x.

39. Yuan W, Varga J. Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. *J Biol Chem* 2001; 276: 38502–38510, doi: 10.1074/jbc.M107081200.

40. Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. *Biochem J* 2006; 393: 601–607, doi: 10.1042/BJ20051106.